AA
TBIO

AlphaCentric Advisors’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

AlphaCentric Advisors’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-16,000
Closed -$264K – 252
2021
Q1 		$264K Buy
+16,000
New +$365K 0.09% 81
2020
Q4 		– Sell
-5,100
Closed -$69K – 241
2020
Q3 		$69K Buy
+5,100
New +$78.6K 0.03% 86

Other funds holding TBIO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AlphaCentric Advisors's TBIO Position: Q2 2021 in Review

AlphaCentric Advisors sold out of Translate Bio, Inc. Common Stock (TBIO) in Q2 2021, closing a stake of 16,000 shares — an estimated $264K sold.

AlphaCentric Advisors first reported a position in TBIO in Q3 2020 and held it in 2 quarters. The position peaked at $264K in Q1 2021. 145 funds tracked by Wall St. Rank hold TBIO as of Q2 2021.

  • AlphaCentric Advisors reported no remaining Translate Bio, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • AlphaCentric Advisors sold 16,000 Translate Bio, Inc. Common Stock shares in Q2 2021, an estimated $264K.
  • AlphaCentric Advisors first reported a position in Translate Bio, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • AlphaCentric Advisors's Translate Bio, Inc. Common Stock position peaked at $264K in Q1 2021.
  • 145 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q2 2021.

Based on AlphaCentric Advisors's 13F filing for Q2 2021, filed 9 Mar 2022.